(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2011 (17.02.2011)

PCT

(10) International Publication Number
WO 2011/019801 A1

(51) International Patent Classification:
A61K 38/00 (2006.01)

(21) International Application Number:
PCT/US2010/045137

(22) International Filing Date:
11 August 2010 (11.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/233,233 12 August 2009 (12.08.2009) US
61/330,944 4 May 2010 (04.05.2010) US

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [US/US]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ANDERSON, Niall** [GB/GB]; Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **BUSCH-PETERSEN, Jakob** [DK/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **EVANS, Brian** [GB/GB]; 18 Freman Drive, Buntington, Hertfordshire SG9 9TD (GB). **LI, Huijie** [CN/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **NEVINS, Neysa** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **PALOVICH, Michael, R.** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **SOLLIS, Steven, L.** [GB/GB]; Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **WALL, Michael, D.** [IE/GB]; Chesterford Research Park, Saffron Walden, Essex CB10 1XL (GB). **BULLION, Ann M.** [US/US]; 709 Swedeland Road, King of Prussia, Pennsylvania 19406 (US).

(74) Agents: **FITCH, Duke, M.** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King Of Prussia, PA 19406-0939 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: CATHEPSIN C INHIBITORS



(I)

(57) **Abstract**: Disclosed are 4-amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.

WO 2011/019801 A1